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Subject Category: Cancer Prostate cancer is one of the most common types of cancer and the second leading cause of cancer death in men (American Cancer Society). Surgery, radiation therapy, and hormone therapy are generally effective for early and localized cancers. However, as the prostate cancers progress to advanced stages and metastasize, chemotherapy is the only option and often fails to produce clinical response. It is known that as the prostate cancers evolve from the benign stage to more aggressive stages, they become more resistant to apoptosis. [1] [2] [3] [4] [5] The resistance to apoptosis has been associated with increased expression of antiapoptotic proteins Bcl-2, survivin, XIAP, and the multidrug resistanceassociated protein, as well as decreased expression of the pro-apoptotic proteins Bax and Bak. The exact mechanism of how advanced prostate cancers evade apoptosis remains poorly defined. microRNAs (miRNAs) are small 19-25 nucleotide-long, single-stranded non-coding RNAs that silence target genes by cleaving mRNA molecules or inhibiting translation. 6 The miRNAs are transcribed from their genes by pol II as long pri-miRNAs and processed into B60-70 nucleotide-long pre-miRNA by Drosha RNase III endonuclease. 7 Another RNase III endonuclease Dicer further processes the pre-miRNAs and the mature single-strand miRNAs are incorporated into the RNA-induced silencing complex (RISC) to recognize and bind to target mRNAs. Recently, miRNAs have been linked to cancer pathogenesis, regulating cell cycle, 8 differentiation, 9,10 metabolism, 11 invasion and metastasis, 12 as well as apoptosis. 13 In cancer cells, tumor suppressor genes (RB1, CDKN2A, CDKN1A, CDH1, GSTP1, and so on.) can be silenced through hypermethylation of the CpG islands within the promoter region.
14 DNA methylation results in the recruitment of proteins containing the methyl-CpG binding domain, which in turn attract histone deacetylases and histone methyltransferases to modify histones and inhibit gene expression. 15 More than 40 genes have been shown to be epigenetically silenced by DNA methylation in prostate cancer. 16 More interestingly, hypermethylation of the promoters of ERa, hMLH1, and p14/INK4a often occurs in advanced prostate cancers. 17 Recently, a number of tumor suppressing miRNAs have been shown to be downregulated in cancer cells by CpG island methylation-associated silencing. [18] [19] [20] [21] [22] [23] Thus, epigenetic silencing of the tumor suppressing miRNAs may contribute as a novel mechanism for cancer development.
WPE1-NA22 and WPE1-NB26 are prostate cancer cell lines derived from immortalized human prostate epithelial RWPE-1 cells by treatment with N-methyl-N-nitrosourea and sequential xenografts in nude mice. 24 Although the WPE1-NA22 cells form small, non-invasive, well-differentiated tumors in nude mice, the WPE1-NB26 cells are highly malignant and form large, poorly differentiated, invasive tumors. We found that WPE1-NB26 cells were highly resistant to apoptosis induced by various agents, whereas WPE1-NA22 cells were sensitive. By comparing the miRNA expression profiles between the two cell lines, we found that miR-205 and miR-31 were significantly downregulated in WPE1-NB26 cells. Downregulation of the two miRNAs resulted in upregulation of antiapoptotic proteins Bcl-w and E2F6 and resistance to apoptosis. We further demonstrated that promoter hypermethylation of the miR-205 gene was responsible for its downregulation in advanced prostate cancer cells.
Results
WPE1-NB26 cells are resistant to various apoptosis stimuli. We compared the WPE1-NA22 (early cancer) and WPE1-NB26 (advanced cancer) prostate cancer cell lines for their responses to various apoptosis-inducing treatments. As shown in Figure 1 , WPE1-NB26 cells were significantly more resistant to apoptosis induced by UV irradiation, H 2 O 2 , and chemotherapeutic agents Docetaxel and Cisplatin, comparing with the WPE1-NA22 cells. Induction of apoptosis was determined by the cell death ELISA assay measuring mono and oligonucleosomes in the lysates of apoptotic cells. The different apoptotic responses between the two cell lines were also confirmed by annexin V staining (Supplementary Figure 1A) . To understand the mechanism that is responsible for the apoptosis resistance in WPE1-NB26 cells, we examined the expression of several apoptosis regulatory proteins (including Bcl-xL, Mcl-1, XIAP, Bid, and Bax) in the two cell lines. However, we did not observe a change in the levels of these apoptosis regulators that can explain the observed resistance in WPE1-NB26 cells. In fact, the levels of both antiapoptotic proteins Mcl-1 and XIAP were decreased in WPE1-NB26 cells, comparing with those in WPE1-NA22 cells (Supplementary Figure 1B) . miR-205 and miR-31 are downregulated in WPE1-NB26 cells. To determine whether differential miRNA expression has a role in the apoptosis resistance in WPE1-NB26 cells, we compared miRNA expression profiles between WPE1-NA22 and WPE1-NB26 cells, using the mirVana miRNA Bioarray. Among the 471 human miRNAs examined, five miRNAs were found to be decreased and five miRNAs were found to be increased in WPE1-NB26 cells (Supplementary Table 1 ). Among these miRNAs, miR-205 and miR-31 were the most significantly downregulated ones in WPE1-NB26 cells, decreased by 93.1 and 77.1% of the levels in WPE1-NA22 cells, respectively. The downregulation of miR-205 and miR-31 in WPE1-NB26 cells were confirmed by real-time PCR (Figure 2 ). We selected these two miRNAs to further study their roles in prostate cancer apoptosis.
miR-205 and miR-31 are downregulated in advanced prostate cancer cells. To determine whether miR-205 and miR-31 are downregulated in other cell lines derived from RWPE-1 and other malignant prostate cancer cell lines, we analyzed the expression levels of the two miRNAs by realtime PCR. As shown in Figure 2 , the expression levels of miR-205 and miR-31 showed sequential decrease as the prostate cancer progresses from WPE1-NA22, WPE1-NB14, WPE1-NB11, to WPE1-NB26, in the order of increasing malignancy. 24 Furthermore shown in Figure 2 Figure 2A and 2B, while RWPE-1 cells were sensitive to Cisplatin-and Docetaxelinduced apoptosis, WPE1-NB14 and WPE1-NB11 cells were resistant to these drugs as the levels of miR-205 and miR-31 were decreased in these cells. Du145 and 22Rv1 cells were relatively resistant to Cisplatin (comparing with RWPE-1 and WPE1-NA22 cells, but to a lesser degree when comparing with PC-3 cells), and both Du145 and PC-3 cells were more resistant to Docetaxel than the 22Rv1 cells (Supplementary Figure 2C and 2D). As these cell lines all express low levels of miR-205 and miR-31, we reason that other drug-resistance mechanisms may contribute to the observed differences among their responses to these agents. However, despite the differences of their responses, they were all relatively resistant to Cisplatin and Docetaxel when compared with the RWPE-1 and WPE1-NA22 cells, which express higher levels of miR-205 and miR-31.
miR-205 targets Bcl-w and miR-31 targets E2F6. Using the computational methods available at http://www.microrna.org and miRBase (http://microrna.sanger.ac.uk/), we identified Bcl-w as the potential target for miR-205, and E2F6 as the potential target for miR-31. Bcl-w is an antiapoptotic member of the Bcl-2 family proteins. 25 E2F6 inhibits UV-and hypoxiainduced apoptosis. 26, 27 The antiapoptotic properties of Bcl-w and E2F6 make them interesting targets for miR-205 and miR-31. The BCL2L2 mRNA (encoding Bcl-w) contains a 3 0 untranslated region (3 0 UTR) sequence that is partially complementary to miR-205, and the E2F6 mRNA has a Bcl-w and E2F6 confer resistance to chemotherapyinduced apoptosis. We expressed Bcl-w and E2F6 exogenously to determine whether these proteins can contribute to apoptosis resistance in prostate cancer cells. To avoid toxicities associated with transient transfection, we created stable WPE1-NA22 cell lines expressing Bcl-w or E2F6. Overexpression of Bcl-w or E2F6 was confirmed by western blotting (Figure 4a and c). When treated with Docetaxel or Cisplatin, two agents used clinically to treat prostate cancer, cells stably expressing Bcl-w were significantly resistant to drug-induced apoptosis, comparing with empty vectortransfected cells (Figure 4a and b) . Similarly, cells stably expressing E2F6 were also resistant to Docetaxel and Cisplatin (Figure 4c and d) . Induction of apoptosis was also measured by annexin V staining (Supplementary Figure 5A and 5B). Bcl-w-and E2F6-conferred resistance to druginduced apoptosis was confirmed by three independent miR-31 levels Figure 5a and c, stable expression of miR-205 and miR-31 was confirmed by real-time PCR analysis. Overexpression of miR-205 sensitized WPE1-NB26 cells to apoptosis induced by both Docetaxel and Cisplatin (Figure 5a and b) . Similarly, stable expression of miR-31 also sensitized WPE1-NB26 cells to apoptosis following exposure to these agents (Figure 5c and d) . Differences in apoptotic responses were also measured by annexin V staining (Supplementary Figure 5C and 5D ). Sensitization to drug-induced apoptosis by miR-205 and miR-31 was confirmed using three independent clones of miR-205 or miR-31 stable expressing cell lines (Supplementary Figure  6C and 6D).
Promoter hypermethylation causes the downregulation of miR-205 in advanced prostate cancer. To determine the mechanism of how miR-205 and miR-31 were downregulated in prostate cancer cells, we explored whether epigenetic silencing by promoter hypermethylation had a role in their expression. We first performed rapid amplification of 5 0 complementary DNA ends (5 0 RACE) experiments to identify the transcription start site and the promoter for the miR-205 gene. The gene encoding miR-205 is located on chromosome 1. The transcription start site for miR-205 was identified and a CpG island was found in the promoter region of the miR-205 gene about 300 base pairs in front of the first exon (Figure 6a) . The CpG island is potential site to be modified by methylation. To determine whether the miR-205 promoter is methylated in prostate cancer cells, we isolated genomic DNAs from various prostate cancer cell lines, treated the DNA with sodium bisulfate, and performed methylation-specific PCR using appropriate primers that could detect the methylated or unmethylated promoter DNAs. As shown in Figure 6b , methylation of the miR-205 CpG island was detected in Du145, PC-3, LNCaP, 22Rv1, WPE1-NB11, WPE1-NB14, and PC-3M cells, but not in WPE1-NA22 and WPE1-NB26 cells. When PC-3M cells were treated with 5-aza-2 0 -deoxycytidine, an inhibitor of the DNA methyltransferase, the level of miR-205 was increased (Figure 6c , top). Conversely, the protein level of Bcl-w was decreased after treatment with 5-aza-2 0 -deoxycytidine (Figure 6c , bottom). Transfection with anti-miR-205 inhibitor blocked the decrease of Bcl-w caused by 5-aza-2 0 -deoxycytidine (Figure 6c, bottom) . We then tested whether 5-aza-2 0 -deoxycytidine can potentiate Cisplatin-induced apoptosis in PC-3M cell. As shown in Figure 6d 0 -deoxycytidine were blocked by synthetic anti-miR-205 inhibitor. We also cloned the miR-31 gene promoter. However, the results of miR-31 promoter methylation studies were inconclusive. While 5-aza-2 0 -deoxycytidine induced a modest increase of miR-31 expression (about 50% increase) in PC-3M cells, it failed to induce miR-31 expression in other prostate cancer cell lines (data not shown).
Discussion
MicroRNAs have been indicated to have important roles in the regulation of cancer cell functions including differentiation, proliferation, apoptosis, and metastasis. 28, 29 In this study, we have demonstrated that miR-205 and miR-31 regulate apoptosis in prostate cancer cells by targeting antiapoptotic proteins Bcl-w and E2F6. In prostate cancer cell lines derived from advanced metastatic cancers, miR-205 and miR-31 are downregulated to contribute to the resistance to chemotherapy-induced apoptosis. Thus, our data have established a mechanistic basis to explain the resistance to chemotherapy often observed in advanced prostate cancers. This study has also identified miR-205 and miR-31 as key targets to improve prostate cancer response to chemotherapy.
It is known that miRNAs can target many mRNAs and Bcl-w and E2F6 are not the sole targets of miR-205 and miR-31. Other genes targeted by these miRNAs could also have a role in prostate cancer apoptosis. However, as shown by our studies using Bcl-w and E2F6 stable expressing cell lines, these two proteins confer strong resistance to chemotherapyinduced apoptosis, supporting a key role in mediating the effects of miR-205 and miR-31 on apoptosis. Bcl-w is a member of the Bcl-2 family proteins 25 and inhibits apoptosis by blocking the intrinsic pathway of apoptosis. 30 E2F6 is a strong transcription repressor and suppresses both UV-and hypoxia-induced apoptosis. 26, 27 It is likely that E2F6 blocks apoptosis by suppressing the expression of certain pro-apoptotic genes. The individual contribution of miR-205 and miR-31 (as well as Bcl-w and E2F6) to apoptotic response in prostate cancer cells remains to be established. From the data shown in our studies using the stable cell lines (Figures 4  and 5) , overexpression of miR-31 alone seems to be sufficient to induce apoptosis in WPE1-NB26 cells at comparable level to WPE1-NA22 cells. In addition, although Bcl-w blocks Cisplatin-induced apoptosis more effectively than E2F6 in the overexpression experiments, miR-31 seems to be more efficient in sensitizing WPE1-NB26 cells to Cisplatin. These observations could be explained by the possible suppression of other target genes with miR-31 overexpression, which may contribute to the increased induction of apoptosis in response to Cisplatin.
Although we found CpG island methylation in the promoter of miR-205 in various advanced prostate cancer cell lines, we did not detect DNA methylation of the miR-205 promoter in WPE1-NB26 cells. Thus, other mechanisms may be behind the downregulation of miR-205 in the WPE1-NB26 cells. Certain types of histone modifications can function as a silencing mechanism independent of DNA methylation. For example, it is found that histone H3K27 trimethylation is responsible for epigenetic silencing of miR-22 independent of promoter methylation. 31 Alternatively, downregulation of the transcription factors that are required for miR-205 expression may contribute to the silencing of the miRNA in WPE1-NB26 cells. Whether DNA methylation contributes to the downregulation of miR-31 in prostate cancer is not clear. Factors discussed above may have a role in the silencing of miR-31. In addition, mutations or deletions of the miR-31 gene may also be key reasons behind the downregulation of the miRNA in prostate cancer.
Our data indicate that downregulation of miR-205 and miR-31 may represent a key step in prostate cancer progression into the more aggressive and chemo-resistant cancers. Strategies to reactivating the expression of these miRNAs (such as the use of 5-aza-2 0 -deoxycytidine in our study) may prove successful to overcome resistance to chemotherapy in advanced prostate cancers. Plasmids construction, miRNA mimics and inhibitors. The 3 0 UTR cDNA fragments of BCL2L2 and E2F6 genes were obtained by PCR using EST clones as templates. The 3 0 UTR cDNAs were inserted into pEGFP-C1 plasmid at the 3 0 end of the EGFP cDNA (Xho I and BamH I). The pEGFP-C1-3 0 UTR plasmids containing mutations within the miRNA recognition sites (AAGG to TTCC mutation for BCL2L2 3 0 UTR, and TTGC to AACG mutation for E2F6 3 0 UTR) were created by PCR using the QuickChange II site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA), following the supplied protocol. The full-length BCL2L2 and E2F6 cDNAs were obtained by PCR using EST clones as templates and constructed into pcDNA3-HA vector for creation of the stable expression cell lines. To construct miRNA expression vectors, double-strand oligoes containing pre-miR-205 or premiR-31 were cloned into pcDNA6.2-GW/EmGFP-miR plasmids (Invitrogen) by directional cloning. For co-transfection of pEGFP-C1-3 0 UTR and miRNA expression vectors, EmGFP was removed using Dra I digestion to create pcDNA6.2-GWmiR-205 and pcDNA6.2-GW-miR-31. miRIDIAN miR-205 and miR-31 mimics (Cat# C-300564-05 and C-300507-05, respectively) and negative control miRNA (Cat# CN-001000-01-05) were purchased from Dharmacon (Lafayette, CO, USA). Anti-miR miRNA inhibitors for miR-205 and miR-31 (ID AM11015 and AM11465, respectively) were purchased from Ambion (Austin, TX, USA). Western blot analysis. Cells were lysed in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS in PBS). Complete protease inhibitor cocktail (Roche) was added to lysis buffer before use. Protein concentration was determined by Bio-Rad DC protein assay (Bio-Rad, Hercules, CA, USA). Protein samples were subjected to SDS-PAGE and transferred to nitrocellulose membrane. The membrane was blocked in 5% non-fat milk in PBS overnight and incubated with primary antibody and subsequently with appropriate horseradish peroxidaseconjugated secondary antibody. Signals were developed with ECL reagents (Pierce, Rockford, IL, USA) and exposure to X-ray films. Anti-Bcl-w polyclonal antibody was purchased from Stressgen or Enzo (Plymouth Meeting, PA, USA). Anti-b-tubulin and anti-E2F6 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Real-time PCR. The miRNA expression was measured by real-time PCR using TaqMan MicroRNA assays (Cat # TM509 for miR205, TM1100 for miR-31) from Applied Biosystems (Foster City, CA, USA). Total RNA was isolated from cells using mirVana miRNA Isolation Kit (Ambion). A measure of 5 mg of total RNA was used in reverse transcription reaction. The cDNAs were used as templates to perform PCR on an Applied Biosystems 7500 Real-time PCR System following the manufacturer's protocol. Relative miRNA expression levels were calculated using 18S RNA as reference.
miRNA expression profiling. Total RNAs were isolated from WPE1-NA22 and WPE1-NB26 cells using the mirVana miRNA Isolation Kit (Ambion). miRNAs were further concentrated with the flashPAGE Fractionator System (Ambion). The miRNAs from WPE1-NA22 and WPE1-NB26 cells were labeled with the mirVana miRNA Labeling Kit (Ambion) with Cy3 or Cy5 Post Labeling Reactive Dye (Amersham Biosciences, Piscataway, NJ, USA), respectively. The probes were then hybridized to the mirVana miRNA Bioarrays (Ambion) overnight. The array slides were scanned with an Aron 4000B Genepix Microarray Scanner and analyzed with the Genepix software (Molecular Devices, Sunnyvale, CA, USA).
5
0 RACE. The transcription start site of miR-205 pri-miRNA was identified by 5 0 RACE experiments with FirstChoice RLM-RACE kit from Ambion, using total RNA isolated from WPE1-NA22 cells as template.
Methylation-specific PCR. The bisulfate conversion of cytosine to uracil of the genomic DNA was performed with the EZ DNA Methylation-Gold kit from Zymo Research (Orange, CA, USA). Methylation-specific PCR was done with the following primers: miR-205 methylated forward, 5 0 -GAGTTTAAGTTGCGT ATGGAAGC-3 0 , reverse, 5 0 -AAAACAAATATTTCTTTTATAATCCGAA-3 0 . miR-205 unmethylated forward, 5 0 -GGAGTTTAAGTTGTGTATGGAAGTG-3 0 , reverse, 5 0 -AA AACAAATATTTCTTTTATAATCCAAA-3 0 . Bisulfite converted methylated and unmethylated human control DNAs (EpiTect PCR Control DNA Set from Qiagen, Valencia, CA, USA) were used as positive control.
Detection of apoptosis. The Cell Death Detection Elisa kit (Roche) was used to detect apoptosis following the manufacturer's protocol. This assay determines apoptosis by measuring mono and oligonucleosomes in the lysates of apoptotic cells. The cell lysates were placed into a streptavidin-coated microplate and incubated with a mixture of anti-histone-biotin and anti-DNA-peroxidase. The amount of peroxidase retained in the immunocomplex was photometrically determined with ABTS as the substrate. Absorbance was measured at 405 nm. For annexin V staining, cells were washed with cold phosphate-buffered saline (PBS) and diluted in annexin-binding buffer at 1 Â 10 6 cells/ml. A volume of 5 ml of annexin V fluorescein conjugate (Invitrogen) was added to each 100 ml of cell suspension and cells were incubated at room temperature for 15 min. After incubation, cells were analyzed by flow cytometry.
Statistical analysis. Differences between the mean values were analyzed for significance using the unpaired two-tailed Student's test for independent samples; Pr0.05 was considered to be statistically significant.
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